23/08/2024 (Agence Europe) – On Friday 23 August, the European Commission authorised the ‘mResvia’ mRNA vaccine (developed by Moderna) to immunise adults over 60 of age against lower respiratory tract disease caused by the respiratory syncytial virus (RSV). This is a common respiratory virus, with generally mild symptoms, but which can have serious consequences for vulnerable people, including the elderly. The authorisation of mResvia comes ahead of the autumn/winter season, when...